A 31-year-old man diagnosed with schizophrenia 18 months ago has been treated with risperidone 4mg daily with good response. Over the past 3 months, he has developed progressive breast enlargement and tenderness, reduced libido, and erectile dysfunction. He is distressed by these symptoms and considering stopping medication. Physical examination confirms bilateral gynaecomastia. Blood tests show: prolactin 3200 mU/L (normal <450). His psychotic symptoms remain well controlled. Which antipsychotic would be the most appropriate alternative?
Q102
A 33-year-old woman with bipolar affective disorder type I has been stable on sodium valproate 1000mg daily for 3 years. She attends for pre-conception counselling as she wishes to become pregnant. She has had two previous manic episodes requiring admission, both when not on medication. She tried lamotrigine previously but discontinued due to rash. She is currently euthymic. What is the most appropriate management of her mood stabiliser for pregnancy planning?
Q103
A 45-year-old man with chronic paranoid schizophrenia has been stable on clozapine 450mg daily for 18 months. He presents to his GP with a 6-week history of progressive heartburn, regurgitation of food, and difficulty swallowing solids. He has gained 8kg since starting clozapine. Examination reveals a BMI of 31 kg/m². There are no signs of infection. Recent clozapine level was therapeutic. ECG shows: HR 105/min, normal sinus rhythm, QTc 425ms. What is the most likely cause of his symptoms?
Q104
A 28-year-old woman presents to the crisis team with a 3-day history of elevated mood, grandiose beliefs that she is a famous singer, pressured speech, and significantly decreased need for sleep. She has spent £15,000 on credit cards buying recording equipment. This is her first psychiatric presentation. She has no medical history and takes no medications. Her mother mentions the patient seemed 'low in mood' for several weeks about 4 months ago but didn't seek help. Urine drug screen is negative. Physical examination and routine blood tests are normal. What is the most appropriate diagnosis?
Q105
A 39-year-old man with a 12-year history of paranoid schizophrenia has been treated with clozapine 600mg daily for the past 3 years with good symptom control. He attends routine blood monitoring. Results show: WBC 3.2 × 10⁹/L, neutrophils 1.4 × 10⁹/L, haemoglobin 142 g/L, platelets 245 × 10⁹/L. He is clinically well with no signs of infection. His previous blood test 1 week ago showed: WBC 4.5 × 10⁹/L, neutrophils 2.5 × 10⁹/L. What is the most appropriate immediate action?
Q106
A 36-year-old woman with bipolar affective disorder type I is admitted to the psychiatric ward with severe mania. She is extremely agitated, verbally aggressive, and has not slept for 4 days. She is physically threatening staff and refuses all oral medication. Her past history includes three previous manic episodes, all requiring admission. Physical examination shows: pulse 110/min, BP 145/92 mmHg, temperature 37.2°C. ECG shows sinus tachycardia. What is the most appropriate immediate pharmacological management?
Q107
A 22-year-old man is assessed in the early intervention service. He presents with a 10-week history of social withdrawal, reduced self-care, bizarre beliefs that he can control the weather, and hearing two voices discussing him in the third person. His mother reports personality change over the past year with declining university performance. There is no substance use. He has no past psychiatric history. What is the minimum duration of symptoms required to diagnose schizophrenia according to ICD-10 criteria?
Q108
A 41-year-old man with bipolar affective disorder type I is reviewed in the outpatient clinic. He has had multiple manic episodes over the past 8 years requiring hospitalisation. He has been on lithium carbonate 800mg daily for 5 years with good effect. Recent blood tests show: lithium level 0.58 mmol/L (therapeutic range 0.6-1.0), sodium 139 mmol/L, potassium 4.2 mmol/L, urea 6.5 mmol/L, creatinine 95 μmol/L, eGFR 72 ml/min, TSH 5.8 mU/L (normal 0.5-5.0), free T4 11 pmol/L (normal 10-22). He reports feeling well with no mood symptoms. What is the most appropriate management?
Q109
A 34-year-old woman with a 7-year history of schizophrenia is brought to A&E by her family. She has been non-compliant with oral risperidone for 6 months. She presents with bizarre behaviour, belief that her neighbours are poisoning her water supply, and auditory hallucinations. She lacks insight into her illness and refuses voluntary treatment. Her family reports this is her fourth relapse due to medication non-adherence. Physical examination is unremarkable. Which long-acting injectable antipsychotic would be the most appropriate first-line depot treatment?
Q110
A 47-year-old man with treatment-resistant paranoid schizophrenia has been taking clozapine 600mg daily for 5 years with partial response. He continues to experience persistent auditory hallucinations and paranoid delusions affecting his quality of life despite optimal clozapine dosing and confirmed therapeutic plasma levels. He has tried clozapine augmentation with amisulpride without benefit. Which intervention has the strongest evidence base for management of his persistent symptoms?
Severe Mental Illness UK Medical PG Practice Questions and MCQs
Question 101: A 31-year-old man diagnosed with schizophrenia 18 months ago has been treated with risperidone 4mg daily with good response. Over the past 3 months, he has developed progressive breast enlargement and tenderness, reduced libido, and erectile dysfunction. He is distressed by these symptoms and considering stopping medication. Physical examination confirms bilateral gynaecomastia. Blood tests show: prolactin 3200 mU/L (normal <450). His psychotic symptoms remain well controlled. Which antipsychotic would be the most appropriate alternative?
A. Amisulpride 400mg daily
B. Haloperidol 5mg daily
C. Aripiprazole 15mg daily (Correct Answer)
D. Paliperidone 6mg daily
E. Olanzapine 15mg daily
Explanation: ***Aripiprazole 15mg daily***
- **Aripiprazole** is a **partial dopamine agonist** at D2 receptors, which means it provides enough dopaminergic activity to prevent the excessive rise of prolactin.
- It is the most appropriate alternative because it is considered **prolactin-sparing** and can even lower prolactin levels when added to other antipsychotics.
*Amisulpride 400mg daily*
- This medication is notorious for causing **hyperprolactinaemia** because it does not cross the **blood-brain barrier** well, leading to high D2 occupancy in the pituitary gland.
- Switching to this would likely worsen or maintain the patient's **gynaecomastia** and sexual dysfunction.
*Haloperidol 5mg daily*
- As a high-potency **first-generation antipsychotic**, haloperidol has a strong propensity to increase prolactin through **tuberoinfundibular pathway** blockade.
- It would not address the patient's current side effects and would increase the risk of **extrapyramidal symptoms**.
*Paliperidone 6mg daily*
- **Paliperidone** is the active metabolite of risperidone and shares a very similar pharmacological profile regarding **D2 receptor antagonism**.
- It is highly associated with **elevated prolactin levels** and would be unlikely to resolve the patient’s clinical symptoms.
*Olanzapine 15mg daily*
- While olanzapine causes less prolactin elevation than risperidone, its effect is not neutral, and it may not fully resolve severe **hyperprolactinaemia**.
- Additionally, it carries a high risk of **metabolic side effects**, such as weight gain and dyslipidaemia, which may not be the optimal trade-off for this patient.
Question 102: A 33-year-old woman with bipolar affective disorder type I has been stable on sodium valproate 1000mg daily for 3 years. She attends for pre-conception counselling as she wishes to become pregnant. She has had two previous manic episodes requiring admission, both when not on medication. She tried lamotrigine previously but discontinued due to rash. She is currently euthymic. What is the most appropriate management of her mood stabiliser for pregnancy planning?
A. Continue sodium valproate and start high-dose folic acid 5mg daily
B. Switch to lithium carbonate with careful monitoring (Correct Answer)
C. Discontinue all mood stabilisers as she is currently stable
D. Switch to quetiapine monotherapy
E. Continue sodium valproate at reduced dose of 500mg daily
Explanation: ***Switch to lithium carbonate with careful monitoring***
- **Sodium valproate** is highly **teratogenic**, posing significant risks of **neurodevelopmental disorders** and neural tube defects, and is contraindicated in pregnancy for women of childbearing potential.
- **Lithium** is the preferred mood stabilizer for bipolar I disorder during pregnancy, as its risk of malformation (primarily **Ebstein's anomaly**) is lower than valproate and manageable with careful monitoring, including **fetal echocardiography**.
*Continue sodium valproate and start high-dose folic acid 5mg daily*
- High-dose **folic acid** can reduce the risk of neural tube defects but does not mitigate the substantial risk of **neurodevelopmental delay** and other malformations associated with valproate exposure.
- Current guidelines strictly prohibit valproate use in women of childbearing age unless part of a **Pregnancy Prevention Programme** and no suitable alternatives exist.
*Discontinue all mood stabilisers as she is currently stable*
- Discontinuing all mood stabilizers for a patient with a history of two **manic episodes requiring admission** carries a very high risk of **relapse**, especially during the **peripartum and postpartum periods**.
- Maintaining mood stability is critical for both maternal health and the safety of the pregnancy, making discontinuation an unsafe option.
*Switch to quetiapine monotherapy*
- While **quetiapine** is an antipsychotic used in bipolar disorder, its efficacy as monotherapy for preventing severe **manic episodes** is not as robust as lithium, particularly in a patient with a history of severe illness.
- Given her previous failure with **lamotrigine**, a more established and effective mood stabilizer like lithium is generally preferred for severe bipolar I disorder.
*Continue sodium valproate at reduced dose of 500mg daily*
- Reducing the dose of **sodium valproate** does not eliminate its **teratogenic risks**; even lower doses are associated with unacceptable risks of fetal harm, including neurodevelopmental issues.
- The management strategy must involve switching to a safer medication altogether, rather than attempting to find a 'safe' dose of a highly teratogenic drug during pregnancy.
Question 103: A 45-year-old man with chronic paranoid schizophrenia has been stable on clozapine 450mg daily for 18 months. He presents to his GP with a 6-week history of progressive heartburn, regurgitation of food, and difficulty swallowing solids. He has gained 8kg since starting clozapine. Examination reveals a BMI of 31 kg/m². There are no signs of infection. Recent clozapine level was therapeutic. ECG shows: HR 105/min, normal sinus rhythm, QTc 425ms. What is the most likely cause of his symptoms?
A. Clozapine-induced gastro-oesophageal reflux disease
B. Clozapine-induced oesophageal hypomotility (Correct Answer)
C. Clozapine-induced constipation with overflow
D. Oesophageal candidiasis secondary to immunosuppression
E. Oesophageal stricture from chronic acid reflux
Explanation: ***Clozapine-induced oesophageal hypomotility***
- Clozapine has potent **antimuscarinic (anticholinergic)** effects that reduce peristalsis throughout the gastrointestinal tract, leading to **delayed oesophageal transit** and dysphagia.
- The clinical presentation of **dysphagia to solids** and food regurgitation is a classic indicator of a motility disorder rather than simple acid reflux.
*Clozapine-induced gastro-oesophageal reflux disease*
- While Clozapine can cause reflux by relaxing the **lower oesophageal sphincter**, it does not typically cause progressive **difficulty swallowing solids**.
- Reflux symptoms are common in patients on Clozapine, but the addition of **dysphagia** points toward a more severe underlying motility issue.
*Clozapine-induced constipation with overflow*
- This condition, known as **Clozapine-induced gastrointestinal hypomotility (CIGH)**, usually affects the lower bowel and presents with abdominal pain or distension.
- It would not explain upper gastrointestinal symptoms like **heartburn and dysphagia** unless it reached the stage of a complete bowel obstruction.
*Oesophageal candidiasis secondary to immunosuppression*
- While Clozapine can cause **agranulocytosis**, there are no signs of active infection, and the patient's neutropenic status is not confirmed here.
- Candidiasis typically presents with **odynophagia (painful swallowing)** and visible oral thrush, which are not described in this case.
*Oesophageal stricture from chronic acid reflux*
- Strictures are a complication of **long-term gastro-oesophageal reflux disease (GORD)** and usually take many years of untreated inflammation to develop.
- It is unlikely for a stricture to cause this level of symptomatology within only **18 months** of starting the causative medication.
Question 104: A 28-year-old woman presents to the crisis team with a 3-day history of elevated mood, grandiose beliefs that she is a famous singer, pressured speech, and significantly decreased need for sleep. She has spent £15,000 on credit cards buying recording equipment. This is her first psychiatric presentation. She has no medical history and takes no medications. Her mother mentions the patient seemed 'low in mood' for several weeks about 4 months ago but didn't seek help. Urine drug screen is negative. Physical examination and routine blood tests are normal. What is the most appropriate diagnosis?
A. Bipolar affective disorder type I
B. Bipolar affective disorder type II
C. Cyclothymia
D. Schizoaffective disorder, manic type
E. Manic episode, single episode (Correct Answer)
Explanation: ***Manic episode, single episode***- This patient is experiencing her **first presentation** of severe mood elevation, grandiosity, and **functional impairment** (spending £15,000), which meets the criteria for a **manic episode**.- Per **ICD-10** criteria, if it is the first such psychiatric event and previous "low mood" was never clinically diagnosed as a depressive episode, it is classified as a **single manic episode**.*Bipolar affective disorder type I*- A diagnosis of **Bipolar I** typically requires at least **two separate mood episodes**, at least one of which must be mania or mixed.- Although the mother reported a period of low mood, this was **not formally diagnosed** or treated, precluding an immediate diagnosis of Bipolar I at the first presentation.*Bipolar affective disorder type II*- This requires at least one **major depressive episode** and at least one **hypomanic episode**.- The patient's symptoms (grandiosity and severe financial recklessness) classify as **full mania**, not hypomania, which excludes Bipolar II.*Cyclothymia*- **Cyclothymia** involves a chronic period of at least **two years** of mood instability with fluctuations between mild depression and hypomania.- The severity and **acute onset** of the patient's manic symptoms (grandiose beliefs) are inconsistent with the low-grade nature of cyclothymic shifts.*Schizoaffective disorder, manic type*- This diagnosis requires **psychotic symptoms** (like hallucinations or delusions) to occur for at least two weeks in the **absence** of prominent mood symptoms.- In this case, the **grandiose beliefs** are occurring concurrently with elevated mood and pressures of speech, suggesting they are mood-congruent features of mania rather than an independent psychotic disorder.
Question 105: A 39-year-old man with a 12-year history of paranoid schizophrenia has been treated with clozapine 600mg daily for the past 3 years with good symptom control. He attends routine blood monitoring. Results show: WBC 3.2 × 10⁹/L, neutrophils 1.4 × 10⁹/L, haemoglobin 142 g/L, platelets 245 × 10⁹/L. He is clinically well with no signs of infection. His previous blood test 1 week ago showed: WBC 4.5 × 10⁹/L, neutrophils 2.5 × 10⁹/L. What is the most appropriate immediate action?
A. Stop clozapine immediately, admit to hospital, and start broad-spectrum antibiotics
B. Stop clozapine immediately and repeat blood test within 24 hours (Correct Answer)
C. Continue clozapine and repeat blood test in 1 week
D. Reduce clozapine dose to 400mg daily and repeat blood test in 3 days
E. Continue clozapine and repeat blood test in 3 days with increased monitoring frequency
Explanation: ***Stop clozapine immediately and repeat blood test within 24 hours***
- This patient's **neutrophil count of 1.4 × 10⁹/L**, following a significant drop from 2.5 × 10⁹/L, meets the criteria for a **Red Signal** or critical neutropenia, mandating immediate cessation of clozapine.
- Repeating the blood test within **24 hours** is crucial for urgent re-evaluation, to confirm the declining trend, and to monitor for any further, potentially rapid, fall in neutrophil count.
*Stop clozapine immediately, admit to hospital, and start broad-spectrum antibiotics*
- While stopping clozapine is correct, **urgent admission to hospital** and initiation of **broad-spectrum antibiotics** are only indicated if the patient shows signs of **infection** or is **clinically unwell**.
- The patient is described as **clinically well** with no signs of infection, so these aggressive measures are premature at this stage.
*Continue clozapine and repeat blood test in 1 week*
- **Continuing clozapine** with a critically low and declining neutrophil count carries a high risk of developing **life-threatening agranulocytosis**.
- Waiting for **1 week** for a repeat blood test is dangerously long, as clozapine-induced neutropenia can progress very rapidly over a few days.
*Reduce clozapine dose to 400mg daily and repeat blood test in 3 days*
- **Clozapine-induced neutropenia** is an **idiosyncratic reaction**, not typically dose-dependent; therefore, **reducing the dose** will not mitigate the risk of severe hematological toxicity.
- The established protocol for significant neutropenia with clozapine is **complete cessation** of the drug, not dose reduction, and repeating the test in **3 days** is too long for this critical situation.
*Continue clozapine and repeat blood test in 3 days with increased monitoring frequency*
- **Continuing clozapine** is unsafe given the significant drop in neutrophil count, which requires immediate cessation as per
Question 106: A 36-year-old woman with bipolar affective disorder type I is admitted to the psychiatric ward with severe mania. She is extremely agitated, verbally aggressive, and has not slept for 4 days. She is physically threatening staff and refuses all oral medication. Her past history includes three previous manic episodes, all requiring admission. Physical examination shows: pulse 110/min, BP 145/92 mmHg, temperature 37.2°C. ECG shows sinus tachycardia. What is the most appropriate immediate pharmacological management?
A. Intramuscular haloperidol 5mg
B. Intramuscular lorazepam 2mg and intramuscular haloperidol 5mg (Correct Answer)
C. Oral lithium carbonate 400mg
D. Intramuscular olanzapine 10mg
E. Intravenous diazepam 10mg
Explanation: ***Intramuscular lorazepam 2mg and intramuscular haloperidol 5mg***
- For **rapid tranquillisation** in severe mania with **agitation, aggression**, and refusal of oral medication, the combination of an **antipsychotic** (haloperidol) and a **benzodiazepine** (lorazepam) is most effective.
- This combination provides immediate **sedation** and helps manage psychotic symptoms synergistically, with the benzodiazepine also helping to mitigate **extrapyramidal side effects** of haloperidol.
*Intramuscular haloperidol 5mg*
- While **haloperidol** is an effective antipsychotic for mania, monotherapy is generally less effective for immediate **behavioral control** in severely agitated patients compared to the combination regimen.
- Using an antipsychotic alone without a benzodiazepine can increase the risk of developing **acute dystonia** and other **extrapyramidal side effects**.
*Oral lithium carbonate 400mg*
- **Lithium** has a **slow onset of action**, typically requiring several days to reach therapeutic levels, making it unsuitable for immediate management of acute agitation and aggression.
- The patient's explicit **refusal of oral medication** makes this option impractical and ineffective in an emergency situation.
*Intramuscular olanzapine 10mg*
- **Intramuscular olanzapine** is an effective agent for acute agitation, but it has a significant contraindication: it should **not be administered concurrently with parenteral benzodiazepines** due to the risk of severe **respiratory depression** and hypotension.
- While an alternative, the haloperidol/lorazepam combination is often preferred as a first-line option for high-risk aggression due to its established safety profile for **rapid tranquillisation**.
*Intravenous diazepam 10mg*
- **Intravenous administration** of benzodiazepines like diazepam for rapid tranquillisation is generally avoided in psychiatric emergencies due to a significantly higher risk of **respiratory arrest** and the need for intensive monitoring, often in an ICU setting.
- The **intramuscular route** is preferred for rapid, safer absorption in these scenarios, providing effective sedation while reducing the risks associated with IV administration.
Question 107: A 22-year-old man is assessed in the early intervention service. He presents with a 10-week history of social withdrawal, reduced self-care, bizarre beliefs that he can control the weather, and hearing two voices discussing him in the third person. His mother reports personality change over the past year with declining university performance. There is no substance use. He has no past psychiatric history. What is the minimum duration of symptoms required to diagnose schizophrenia according to ICD-10 criteria?
A. 2 weeks
B. 4 weeks
C. 1 month (Correct Answer)
D. 6 weeks
E. 3 months
Explanation: ***1 month***
- According to **ICD-10 criteria**, the characteristic symptoms of schizophrenia must be present for the majority of the time during a period of at least **one month**.
- This duration criterion helps distinguish schizophrenia from **acute and transient psychotic disorders**, which have a shorter duration.
*2 weeks*
- A two-week duration is insufficient for a diagnosis of schizophrenia under both **ICD-10** and **DSM-5** frameworks.
- This timeframe is more commonly associated with the minimum duration required to diagnose a **depressive episode**.
*4 weeks*
- While four weeks is approximately one month, the **ICD-10** specifically defines the requirement as **one month**.
- Using "weeks" as a metric is statistically less precise than the defined **monthly clinical requirement** for formal diagnosis.
*6 weeks*
- A six-week duration exceeds the minimum **ICD-10** requirement of one month, meaning the patient already met the criteria two weeks prior.
- It does not represent the **earliest threshold** required for a clinician to confirm the diagnosis of schizophrenia.
*3 months*
- A three-month timeframe is not a standard diagnostic threshold for the primary diagnosis of **schizophrenia** in major classification systems.
- This duration is more relevant to certain **delusional disorders** or chronic monitoring rather than the minimum diagnostic criteria.
Question 108: A 41-year-old man with bipolar affective disorder type I is reviewed in the outpatient clinic. He has had multiple manic episodes over the past 8 years requiring hospitalisation. He has been on lithium carbonate 800mg daily for 5 years with good effect. Recent blood tests show: lithium level 0.58 mmol/L (therapeutic range 0.6-1.0), sodium 139 mmol/L, potassium 4.2 mmol/L, urea 6.5 mmol/L, creatinine 95 μmol/L, eGFR 72 ml/min, TSH 5.8 mU/L (normal 0.5-5.0), free T4 11 pmol/L (normal 10-22). He reports feeling well with no mood symptoms. What is the most appropriate management?
A. Increase lithium dose to achieve therapeutic level
B. Continue current lithium dose and monitor lithium level in 3 months
C. Start levothyroxine and continue current lithium dose (Correct Answer)
D. Switch from lithium to sodium valproate
E. Add lamotrigine to current lithium treatment
Explanation: ***Start levothyroxine and continue current lithium dose***
- The patient has **elevated TSH** (5.8 mU/L) with **normal free T4**, indicative of **subclinical hypothyroidism**, a common side effect of **lithium**. Starting **levothyroxine** is appropriate to prevent symptomatic progression.
- Despite a lithium level of 0.58 mmol/L, the patient has been **clinically stable** for 5 years with no mood symptoms, indicating the current dose is effective for prophylaxis.
*Increase lithium dose to achieve therapeutic level*
- The patient is **euthymic** and stable, so increasing the lithium dose is unnecessary and could risk **lithium toxicity**, especially given his mildly reduced **eGFR** (72 ml/min).
- A higher lithium dose could also worsen the existing **thyroid dysfunction**, as lithium is known to cause hypothyroidism.
*Continue current lithium dose and monitor lithium level in 3 months*
- This approach neglects the **elevated TSH**, which signifies established **subclinical hypothyroidism** that requires intervention rather than just observation.
- Active management with **levothyroxine** is needed to address the **endocrine abnormality** induced by lithium.
*Switch from lithium to sodium valproate*
- Switching is not indicated as the patient has demonstrated a **good and stable response** to lithium for 5 years, and the **hypothyroidism** is a treatable side effect.
- Lithium is a highly effective mood stabilizer for **bipolar disorder**, and an unnecessary switch risks precipitating a **relapse of manic episodes**.
*Add lamotrigine to current lithium treatment*
- Lamotrigine is primarily used for **bipolar depression prophylaxis** and is not indicated here as the patient is currently **euthymic** and not experiencing depressive symptoms.
- Adding an additional medication does not address the **lithium-induced hypothyroidism** and introduces unnecessary polypharmacy.
Question 109: A 34-year-old woman with a 7-year history of schizophrenia is brought to A&E by her family. She has been non-compliant with oral risperidone for 6 months. She presents with bizarre behaviour, belief that her neighbours are poisoning her water supply, and auditory hallucinations. She lacks insight into her illness and refuses voluntary treatment. Her family reports this is her fourth relapse due to medication non-adherence. Physical examination is unremarkable. Which long-acting injectable antipsychotic would be the most appropriate first-line depot treatment?
A. Paliperidone palmitate monthly
B. Aripiprazole monthly
C. Flupentixol decanoate fortnightly
D. Risperidone long-acting injection fortnightly (Correct Answer)
E. Olanzapine pamoate monthly
Explanation: ***Risperidone long-acting injection fortnightly***
- Since the patient was previously treated with **oral risperidone**, moving to the long-acting injectable (LAI) form is the most appropriate step to ensure **continuity of care** and predictability of response.
- **Risperidone LAI** is highly effective for managing relapses associated with **medication non-adherence**, though it requires oral supplementation during the initial three weeks.
*Paliperidone palmitate monthly*
- While this is the active metabolite of risperidone and offers a convenient monthly dosing schedule, it is generally considered if the direct **depot equivalent** of her previous medication is not chosen first.
- In clinical practice, if a patient has already shown **tolerability** to oral risperidone, the risperidone-specific LAI is the logical first-line transition.
*Aripiprazole monthly*
- This requires establishing **oral tolerability** and a specific lead-in period which may not be as straightforward as continuing the drug class she was previously prescribed.
- Switching to a different class of antipsychotic (Partial Agonist) during an acute **psychotic relapse** is less ideal than optimizing the current regimen.
*Flupentixol decanoate fortnightly*
- This is a **first-generation antipsychotic (FGA)** depot which carries a significantly higher risk of **extrapyramidal side effects (EPSEs)** compared to second-generation options.
- It is not preferred as a first-line depot choice when the patient has been managed on a **second-generation antipsychotic (SGA)** like risperidone.
*Olanzapine pamoate monthly*
- Use of this injectable is often restricted due to the risk of **post-injection delirium sedation syndrome (PDSS)**, requiring strict monitoring for 3 hours post-dose.
- Due to the administrative burden and **metabolic side effects**, it is rarely selected as the first-line depot option for a patient previously on risperidone.
Question 110: A 47-year-old man with treatment-resistant paranoid schizophrenia has been taking clozapine 600mg daily for 5 years with partial response. He continues to experience persistent auditory hallucinations and paranoid delusions affecting his quality of life despite optimal clozapine dosing and confirmed therapeutic plasma levels. He has tried clozapine augmentation with amisulpride without benefit. Which intervention has the strongest evidence base for management of his persistent symptoms?
A. Add lamotrigine 200mg daily to augment clozapine
B. Refer for cognitive behavioural therapy for psychosis (Correct Answer)
C. Switch from clozapine to long-acting injectable paliperidone
D. Add sodium valproate for mood stabilization
E. Increase clozapine to 900mg daily
Explanation: ***Refer for cognitive behavioural therapy for psychosis***
- **Cognitive Behavioural Therapy for psychosis (CBTp)** is a recommended intervention for patients with **persistent positive symptoms** (e.g., hallucinations, delusions) despite optimal clozapine treatment, according to major clinical guidelines.
- **CBTp** helps patients develop **coping strategies** and alter their interpretations of psychotic experiences, leading to reduced distress and improved quality of life.
*Add lamotrigine 200mg daily to augment clozapine*
- While **lamotrigine** has some evidence as a clozapine augmentation strategy, particularly for negative or mood symptoms, its efficacy for persistent positive symptoms is not as strongly established as **CBTp**.
- It is typically considered a secondary pharmacological option if psychological interventions and other augmentations have not been effective.
*Switch from clozapine to long-acting injectable paliperidone*
- **Clozapine** is the most effective antipsychotic for **treatment-resistant schizophrenia**, and switching from it is rarely recommended unless there are severe adverse effects or non-compliance.
- The patient has been on clozapine for 5 years with partial response, indicating some benefit, and paliperidone is not superior to clozapine for treatment resistance.
*Add sodium valproate for mood stabilization*
- **Sodium valproate** is primarily an **anticonvulsant** and **mood stabilizer** and is typically used for comorbid mood symptoms, aggression, or catatonia in schizophrenia, not as a direct augmentation for persistent positive symptoms.
- The patient's primary symptoms are auditory hallucinations and paranoid delusions, not mood instability, making this a less targeted intervention.
*Increase clozapine to 900mg daily*
- The patient is already on **clozapine 600mg daily** with **confirmed therapeutic plasma levels**; increasing the dose further is unlikely to provide additional benefit for symptoms.
- Doses above 600mg increase the risk of **adverse effects** (e.g., seizures, agranulocytosis, myocarditis) without a proportional increase in efficacy when therapeutic levels are already achieved.
